Mereo BioPharma Group plc (ADR)
General ticker "MREO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $213.4M (TTM average)
Mereo BioPharma Group plc (ADR) does not follow the US Stock Market performance with the rate: -24.5%.
Estimated limits based on current volatility of 2.3%: low 0.31$, high 0.33$
Factors to consider:
- Total employees count: 39 (+8.3%) as of 2025
- Top business risk factors: Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Funding shortfall, Key person loss
- Current price 73.3% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.16$, 2.74$]
- 2026-12-31 to 2027-12-31 estimated range: [1.25$, 2.88$]
Financial Metrics affecting the MREO estimates:
- Positive: with PPE of -26.8 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Shareholder equity ratio, % of 89.11 > 64.23
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.01 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.10 <= 0.74
Short-term MREO quotes
Long-term MREO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $10.00MM | $0.00MM | $0.50MM |
| Operating Expenses | $38.42MM | $47.36MM | $38.76MM |
| Operating Income | $-28.42MM | $-47.36MM | $-38.26MM |
| Non-Operating Income | $-1.58MM | $4.11MM | $-3.62MM |
| Interest Expense | $2.88MM | $1.37MM | $0.26MM |
| R&D Expense | $17.42MM | $20.93MM | $17.77MM |
| Income(Loss) | $-30.00MM | $-43.25MM | $-41.88MM |
| Taxes | $-0.53MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-29.47MM | $-43.25MM | $-41.88MM |
| Stockholders Equity | $50.54MM | $60.97MM | $40.92MM |
| Assets | $66.50MM | $76.39MM | $45.92MM |
| Operating Cash Flow | $-21.13MM | $-32.83MM | $-30.97MM |
| Capital expenditure | $0.42MM | $0.70MM | $0.02MM |
| Investing Cash Flow | $-0.42MM | $-0.70MM | $-0.02MM |
| Financing Cash Flow | $7.97MM | $46.15MM | $0.33MM |
| Earnings Per Share** | $-0.22 | $-0.29 | $-0.26 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.